You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 375,000 shares of its common stock at the public offering price.
Proceeds from the offerings will be used to finance a portion of the cash consideration in connection with BD's $24 billion acquisition of C.R. Bard.
The company intends to sell up to $75 million of its common stock for working capital and other purposes.
The company said it expects to net around $8.4 million, which it will use for working capital and general corporate purposes.
The company intends to use the proceeds for working capital, to repay debt, and for general corporate purposes.
The company said it will use the proceeds for working capital, to repay debt and other liabilities, and for general corporate purposes.
The company said it will use the proceeds for working capital, repayment of indebtedness, and general corporate purposes.
Certain investors have agreed to buy 375,000 shares of Interpaces common stock at $6.75 per share, and 255,000 prefunded warrants to purchase common stock at $6.74 per share.
The Toronto company raised C$721,000 of its previously announced offering that targeted up to C$3 million.
A single institutional investor will purchase 2 million shares of Interpace's common stock and 1.6 million prefunded warrants to purchase its common stock.